# RDHL catalysts: RedHill Biopharma Ltd. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/rdhl/catalysts

> RedHill Biopharma Ltd. (RDHL) has no upcoming catalysts in this calendar. The latest recorded is the rifamycin sv-mmx primary completion, June 2025.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | RedHill Biopharma Ltd. |
| Ticker | RDHL (Nasdaq) |
| SEC CIK | 1553846 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/rdhl |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| January 31, 2014 | [Rizafilm (rizatriptan benzoate) complete response letter (CRL)](https://sec-api.dev/pdufa/rizatriptan-benzoate) | RDHL |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22205394_2023_Orig1s000OtherActionLtrs.pdf%22)) |
| Sep 2023 | [Talicia (talicia) label expansion decision](https://sec-api.dev/pdufa/talicia) | RDHL |  | completed, approved | "In September 2023, we announced that the FDA had approved our supplemental new drug application (sNDA) for Talicia®, allowing a change in dosing to a more flexible schedule, enabling patients to take Talicia® three times daily, at least 4 hours apart with food." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1553846/000110465926049055/rdhl-20251231x20f.htm)) |
| June 2025 | [Rifamycin sv-mmx primary completion](https://sec-api.dev/pdufa/rifamycin-sv-mmx) | RDHL | Traveler's Diarrhea | delayed | "NCT04026984 (Evaluate Safety and Efficacy of Rifamycin SV MMX in the Treatment of Traveler's Diarrhea in Children Age 6 to 11 Years): Overall Status UNKNOWN; Phase PHASE2; Primary Completion 2025-06 (ESTIMATED); Lead Sponsor RedHill Biopharma Limited." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04026984)) |

## Drugs

- [Rifamycin sv-mmx](https://sec-api.dev/pdufa/rifamycin-sv-mmx): Traveler's Diarrhea
- [Rizafilm (rizatriptan benzoate)](https://sec-api.dev/pdufa/rizatriptan-benzoate): 
- [Talicia (talicia)](https://sec-api.dev/pdufa/talicia): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/rdhl/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "RDHL catalysts: RedHill Biopharma Ltd. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/rdhl/catalysts

```bibtex
@misc{secapidev_companies_rdhl_catalysts_20261116,
  title        = {RDHL catalysts: RedHill Biopharma Ltd. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/rdhl/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_rdhl_catalysts_20261116","title":"RDHL catalysts: RedHill Biopharma Ltd. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/rdhl/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
